Alkermes plc and CRISPR Therapeutics AG: SG&A Spending Patterns Compared

A Tale of Two Biotechs: SG&A Spending Trends

In the dynamic world of biotechnology, understanding financial strategies is crucial. Alkermes plc and CRISPR Therapeutics AG, two prominent players, have shown distinct patterns in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Alkermes plc's SG&A expenses surged by approximately 245%, reflecting a strategic focus on expanding operations and market presence. In contrast, CRISPR Therapeutics AG, a pioneer in gene-editing technology, exhibited a more modest increase of around 1,390% in the same period, indicative of its rapid growth phase.

Alkermes consistently outspent CRISPR, with 2023 figures showing nearly nine times higher SG&A expenses. This disparity highlights differing business models: Alkermes' established market position versus CRISPR's innovative, yet nascent, trajectory. As these companies navigate the competitive biotech landscape, their financial strategies offer valuable insights into their future directions.